2023 Fiscal Year Final Research Report
Clinical pharmacology for clinical implementation of pharmacogenomic testing
| Project/Area Number |
21K06665
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 47060:Clinical pharmacy-related
|
|---|
| Research Institution | Kyoto University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2021-04-01 – 2024-03-31
|
| Keywords | 個別医療 / 遺伝子多型 / 薬物動態 / ファーマコゲノミクス |
|---|
| Outline of Final Research Achievements |
Pharmacogenomics (PGx) testing enables prediction of drug efficacy and side effects by analyzing genetic polymorphisms of drug-metabolizing enzymes and drug transporters. Therefore, PGx is an effective tool to realize “Precision Medicine”. In this study, we conducted a retrospective clinical study using a PGx database implemented in electronic medical records, aiming at the clinical dissemination of PGx tests.
Clopidogrel, antiplatelet drug, is metabolically activated by CYP2C19. Conversely, prasugrel is considered to be less involved in CYP2C19. In the present study, we analyzed the impact of PGx testing before antiplatelet therapy on therapeutic efficacy, adverse event occurrence, and pharmacoeconomic effects. It was founded that the utility of PGx testing for appropriate drug selection.
|
| Free Research Field |
医療薬学
|
| Academic Significance and Societal Importance of the Research Achievements |
PGxに関する研究は数多く報告があるが、実臨床におけるPGx検査の有用性に関する検証は充分ではなく、そのため臨床普及も進まないというジレンマに陥っている。本研究計画では臨床業務の一環として実施されているPGx検査のデータベースに基づき、個々の患者に合わせた適切な薬剤選択・投与量決定につながる知見を得た。これにより、治療効率の向上や有害事象の回避などの医学的なメリットに加え、投与量の最適化による薬剤経済学的なメリットが期待できることから、社会的意義も大きいと考える。
|
